ABIVAX Société Anonyme (NASDAQ:ABVX) Now Covered by BTIG Research

BTIG Research began coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVXFree Report) in a research note issued to investors on Monday, Marketbeat reports. The brokerage issued a buy rating and a $43.00 target price on the stock.

ABVX has been the topic of a number of other research reports. Guggenheim began coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They set a buy rating and a $50.00 price target on the stock. Piper Sandler began coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They set an overweight rating and a $42.00 price target on the stock. Finally, Morgan Stanley increased their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an equal weight rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $34.20.

Check Out Our Latest Research Report on ABVX

ABIVAX Société Anonyme Trading Down 0.1 %

Shares of ABVX stock opened at $14.30 on Monday. The business’s 50 day moving average is $14.67 and its two-hundred day moving average is $12.70. ABIVAX Société Anonyme has a 12-month low of $7.99 and a 12-month high of $17.02.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its position in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of ABIVAX Société Anonyme in the first quarter valued at approximately $81,000. Capstone Investment Advisors LLC lifted its position in ABIVAX Société Anonyme by 9.0% during the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after buying an additional 5,199 shares in the last quarter. Finally, Blackstone Inc. purchased a new position in ABIVAX Société Anonyme during the fourth quarter worth approximately $25,345,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

(Get Free Report)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Read More

Analyst Recommendations for ABIVAX Société Anonyme (NASDAQ:ABVX)

Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.